SCHEMBL6523290

SCHEMBL6523290

CCNC(=O)c1ccc(-c2ccc(OC3CN(Cc4ccc(C(C)C)cc4)C3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
ACACB O00763 4/20 0.46
LMNA P02545 1/20 0.42
MCHR1 Q99705 3/20 0.42
KCNH2 Q12809 1/20 0.42
BCHE P06276 1/20 0.42
MAOB P27338 1/20 0.42
HRH3 Q9Y5N1 2/20 0.42
PTPN1 P18031 1/20 0.42
CYP2D6 P10635 1/20 0.41
CHRM1 P11229 1/20 0.41
HTR2A P28223 1/20 0.41
UTS2R Q9UKP6 1/20 0.41
ADRB2 P07550 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660641 0.86 MEN1 (0.57) MEN1KMT2AMCHR1KCNH2BCHE
SCHEMBL12788185 0.86 MEN1 (0.51) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL12788206 0.86 KMT2A (0.51) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL3656142 0.86 ADRB2 (0.52) KCNH2CHRM1HTR2AADRB2
SCHEMBL6522775 0.85 MEN1 (0.56) MEN1KMT2AMCHR1KCNH2BCHE
SCHEMBL3659215 0.84 MEN1 (0.53) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL6521805 0.82 KMT2A (0.78) MEN1KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL3660145 0.80 GCG (0.47) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL12788189 0.80 MEN1 (0.44) MEN1KMT2ARAB9ASMN1; SMN2MCHR1
SCHEMBL12788205 0.79 MEN1 (0.50) MEN1KMT2AMCHR1KCNH2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 US disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists GPR119, GIPR, GPR39 MEN1 2395/4885KMT2A 3734/4885RAB9A 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.